(Q46909611)

26 December 2017

title

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma (English)

1 reference

26 December 2017

author name string

Scott T Tagawa

1

1 reference

26 December 2017

Peter Lee

2

1 reference

26 December 2017

Jolie Snively

3

1 reference

26 December 2017

William Boswell

4

1 reference

26 December 2017

Song Ounpraseuth

5

1 reference

26 December 2017

Sandra Lee

6

1 reference

26 December 2017

Barbara Hickingbottom

7

1 reference

26 December 2017

John Smith

8

1 reference

26 December 2017

Denise Johnson

9

1 reference

26 December 2017

Jeffrey S Weber

10

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

26 December 2017

number of pages

11

1 reference

inferred from page(s)

published in

Cancer

1 reference

26 December 2017

volume

98

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

144-154

1 reference

26 December 2017

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Direct gene transfer into mouse muscle in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Expression of a viral protein by muscle cells in vivo induces protective cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.11462

1 reference

7 January 2021

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Gene vaccination with naked plasmid DNA: mechanism of CTL priming

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Intralymphatic immunization enhances DNA vaccination.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

On T cell memory: arguments for antigen dependence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

On the role of antigen in maintaining cytotoxic T-cell memory

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Immunophenotyping of melanomas for tyrosinase: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11462

7 January 2021

Identifiers

DOI

10.1002/CNCR.11462

1 reference

26 December 2017

1 reference

26 December 2017